Affymax folds after drug withdrawal


Biotech firm Affymax is to be dissolved after post-marketing reports of serious hypersensitivity reactions prompted it to recall its anaemia drug Omontys (peginesatide).

An investigation in conjunction with its marketing partner Takeda found no quality or manufacturing issues with Omontys. However, it also failed to identify any specific root cause for the allergic reactions, so the companies were left with no option but to withdraw the product. Takeda has broken off its marketing agreement with Affymax, effective from 10 September and, subject to shareholder approval, the company will be liquidated .

Omontys is a PEGylated peptide drug used to treat anaemia caused by chronic kidney disease.


Related Content

Folding rules used to build unnatural proteins

27 October 2014 Research

news image

Understanding protein folding and stability leads to new proteins with hopes of creating structures that can perform novel ch...

Chemistry's grand challenges

28 August 2013 Premium contentFeature

news image

What are the big problems for the next generation of chemists to work on? Mark Peplow takes up the gauntlet

Most Read

Self-cleaning sensors see the light

23 January 2015 Research

news image

Overcoming electrode fouling in biomedical and environmental detectors

Alkali metal explosion explained

26 January 2015 Research

news image

High-speed cameras help re-examine the chemistry behind a classic classroom demonstration